Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer - Kirschbrown, Whitney. P. (Clinical Pharmacology. Genentech Research and Early Development) ; Wang, B. (Clinical Pharmacology. Genentech Research and Early Development) ; Nijem, I. (Clinical Pharmacology. Genentech Research and Early Development) ; Ohtsu, A. (Department of Gastrointestinal Oncology. National Cancer Center Hospital East) ; Hoff, P. M. (Instituto do Câncer de São Paulo. Faculdade de Medicina da Universidade de São Paulo) ; Shah, M. A. (Medical Oncology/Solid Tumor Program. Sandra and Edward Meyer Cancer Center. Weill Cornell Medical College) ; Shen, L. (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing). Department of Gastrointestinal Oncology. Peking University Cancer Hospital and Institute) ; Kang, Y. K. (Department of Oncology. Asan Medical Center. University of Ulsan College of Medicine) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Girish, S. (Clinical Pharmacology. Genentech Research and Early Development) ; Garg, Amit (Clinical Pharmacology. Genentech Research and Early Development) ; Universitat Autònoma de Barcelona
 
Comments (0) | Reviews (0)
Start a discussion about any aspect of this document.

 Subscribe to this discussion. You will then receive all new comments by email.

Add comment


Once logged in, authorized users can also attach files.
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.
          You can use some HTML tags: <a href>, <strong>, <blockquote>, <br />, <p>, <em>, <ul>, <li>, <b>, <i>